Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.53 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CDC25A | P30304 | 1/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2638014 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL3983857 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL31432721 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL3182833 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL22721397 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL1341976 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL6666152 | 0.98 | FABP3 (0.52) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL617162 | 0.92 | ALDH1A1 (0.53) | FABP3SMN1; SMN2NR5A2NR5A1 | |
| SCHEMBL1643923 | 0.87 | FABP3 (0.62) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL5475892 | 0.87 | FABP3 (0.62) | FABP3SMN1; SMN2NR5A2NR5A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3893909-A2 | KRAS VARIANT MRNA MOLECULES | CureVac AG (DE) | 2021-10-20 | — | — | EP | claimed |
| WO-2020123300-A2 | KRAS VARIANT MRNA MOLECULES | ELI LILLY AND COMPANY (US) | 2020-06-18 | — | — | WO | claimed |
| US-5626867-A | LIPOSOME FOR CYTOTOXIC AGENTS | MAX-PLANCK GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1997-05-06 | — | — | US | claimed |
| US-12528855-B2 | KRAS variant mRNA molecules | CureVac SE (DE) | 2026-01-20 | — | — | US | disclosed |
| EP-4636090-A1 | UTR FOR IMPROVING TRANSLATION EFFICIENCY AND/OR STABILITY OF RNA MOLECULE AND USE THEREOF | Shenzhen Shenxin Biotechnology Co., Ltd. (CN) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025047645-A1 | METHOD FOR SIMULTANEOUS DETECTION OF BIOMOLECULES USING TEMPERATURE-RESPONSIVE FLUORESCENT PARTICLES | 学校法人早稲田大学 | 2025-03-06 | — | — | WO | disclosed |
| US-20220340641-A1 | KRAS VARIANT MRNA MOLECULES | CUREVAC AG (DE) | 2022-10-27 | — | — | US | disclosed |
| US-11369697-B2 | Liposome nanoparticles for tumor magnetic resonance imaging | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-06-28 | — | — | US | disclosed |
| EP-3893909-A2 | KRAS VARIANT MRNA MOLECULES | CureVac AG (DE) | 2021-10-20 | — | — | EP | disclosed |
| US-10918599-B2 | Serum-stable compositions and methods for light-triggered release of materials | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-02-16 | — | — | US | disclosed |
| EP-3283056-B1 | NANOSTRUCTURES COMPRISING COBALT PORPHYRIN-PHOSPHOLIPID CONJUGATES AND POLYHISTIDINE-TAGS | THE RESEARCH FOUNDATION FOR THE STATE UNIV OF NEW YORK UNIV AT BUFFALO (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20130129636-A1 | Novel Liposome Nanoparticles for Tumor Magnetic Resonance Imaging | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| EP-2501415-A1 | LIPOSOME NANOPARTICLES FOR TUMOR MAGNETIC RESONANCE IMAGING | Medical Research Council (GB) | 2012-09-26 | — | — | EP | disclosed |
| EP-2338525-A2 | Remote detection of substance delivery to cells | California Pacific Medical Center (US) | 2011-06-29 | — | — | EP | disclosed |
| WO-2011061541-A1 | LIPOSOME NANOPARTICLES FOR TUMOR MAGNETIC RESONANCE IMAGING | MEDICAL RESEARCH COUNCIL (GB) | 2011-05-26 | — | — | WO | disclosed |
| US-20110104261-A1 | REMOTE DETECTION OF SUBSTANCE DELIVERY TO CELLS | SUTTER WEST BAY HOSPITALS, DBA | 2011-05-05 | — | — | US | disclosed |
| EP-1648299-A4 | REMOTE DETECTION OF SUBSTANCE DELIVERY TO CELLS | CALIFORNIA PACIFIC MED CENTER (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1648299-A1 | REMOTE DETECTION OF SUBSTANCE DELIVERY TO CELLS | California Pacific Medical Center (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050112065-A1 | Remote detection of substance delivery to cells | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2005-05-26 | — | — | US | disclosed |
| WO-2005016141-A1 | REMOTE DETECTION OF SUBSTANCE DELIVERY TO CELLS | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528855-B2 | KRAS variant mRNA molecules | KRAS, NRAS, TP53 | FABP3 1397/4885SMN1; SMN2 1483/4885NR5A2 3974/4885 |
| US-11369697-B2 | Liposome nanoparticles for tumor magnetic resonance imaging | PHOSPHO1, SGMS1, SGMS2 | FABP3 2257/4885SMN1; SMN2 1993/4885NR5A2 3233/4885 |
| US-20220340641-A1 | KRAS VARIANT MRNA MOLECULES | KRAS, NRAS, APC | FABP3 4547/4885SMN1; SMN2 2467/4885NR5A2 2920/4885 |
| US-10918599-B2 | Serum-stable compositions and methods for light-triggered release of materials | PLTP, PHOSPHO1, TTPA | FABP3 55/4885SMN1; SMN2 2392/4885NR5A2 4150/4885 |
| US-20130129636-A1 | Novel Liposome Nanoparticles for Tumor Magnetic Resonance Imaging | PHOSPHO1, SGMS1, SGMS2 | FABP3 1328/4885SMN1; SMN2 1418/4885NR5A2 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.